The Effects of Glucagon on Renal Regional Blood Flow in Humans Measured by Magnetic Resonance.
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Glucagon, Glucagon+Exendin9-39, Sodium chloride.
- Who it may be relevant to
- Registry conditions: Kidney Diseases. Basic parameters: 20 years — 60 years · Male.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This study will investigating the effects of glucagon on renal blood flow in humans using MRI technology. Glucagon, a hormone produced by the pancreas, plays a key role in regulating blood sugar levels. It has been shown to affect renal function, including electrolyte balance and blood flow, especially in conditions like type 2 diabetes where abnormal glucagon levels are common. The study aims to understand how glucagon affects regional blood flow in the kidneys, specifically the cortex and medulla, and whether these effects are mediated by glucagon receptors. The study will be conducted on 10 healthy male participants aged 20-60 years. It involves three test days where participants will receive either glucagon, glucagon with a GLP-1 receptor antagonist, or placebo. Blood flow, glomerular filtration rate, and other renal functions will be measured using MRI. The study seeks to clarify whether glucagon's effects on the kidneys are linked to changes in regional blood flow and to determine if these effects are mediated solely by glucagon receptors.
Interventions
- Drug Glucagon
Glucagon infusion at 5 ng·kg-¹·min-¹ from 0-30 minutes and 10 ng·kg-¹·min-¹ from 30-60 minutes. - Drug Glucagon+Exendin9-39
Glucagon infusion at 5 ng·kg-¹·min-¹ from 0-30 minutes and 10 ng·kg-¹·min-¹ from 30-60 minutes, plus a GLP-1R antagonist, exendin 9-39 (900 pmol·kg-¹·min-¹), given intravenously from -30 to 60 minutes - Drug Sodium chloride
Placebo (0.9% NaCl).
Primary outcome measures
- Blood perfusion of the kidney [Time frame: 7 measurements of 10 minutes each from the start of infusion (time 0) and up to one hour (time 60).]
Secondary outcome measures (2)
- Blood flow of the renal arteries [Time frame: 7 measurements of 10 minutes each from the start of infusion (time 0) and up to one hour (time 60).]
- blood oxygen saturation of the kidneys [Time frame: 7 measurements of 10 minutes each from the start of infusion (time 0) and up to one hour (time 60).]
Eligibility criteria
Inclusion criteria
- Normal health confirmed through; Interview and Medical examination
- Normal values with respect to blood concentrations of fasting plasma glucose, fasting plasma total cholesterol, fasting triglycerides, HDL, LDL, creatinine, liver function tests, and electrolytes
- Informed consent
Exclusion criteria
- Immunosuppressive treatment in the previous 12 months
- Alcohol abuse
- Medical treatment with oral glucocorticoids, dipeptidyl peptidase-4 (DPP-4) inhibitors, or GLP-1 receptor agonists, which, in the opinion of the principal investigator, may interfere with glucose metabolism
- Use of lithium
- Medical treatment that affects insulin secretion or the renin-angiotensin-aldosterone system
- Liver disease (ALT > 2x normal value)
- Renal impairment (serum creatinine > 130 µM and/or albuminuria)
- Individuals with severe claustrophobia
- Individuals with MR-incompatible foreign bodies
- Individuals with hypertension
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple blind
- Primary purpose
- Basic science
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT06872060 · H-24012271